Versant Venture Management, LLC holds a concentrated book of 7 stocks worth $151.1M as of Q4 2025 (disclosed Feb 12, 2026, a ~43-day 13F lag). This quarter they opened Gritstone Bio Inc and trimmed Monte Rosa Therapeutics Inc. Their largest long position is Monte Rosa Therapeutics Inc at 45% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
No buys this quarter.
Other tracked managers holding the same core names as Versant Venture Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 7 / 7 | $517.7M |
| GEODE CAPITAL MANAGEMENT, LLC | 7 / 7 | $218.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7 / 7 | $156.8M |
| UBS Group AG | 7 / 7 | $91.7M |
| NORTHERN TRUST CORP | 7 / 7 | $57.8M |
| MORGAN STANLEY | 7 / 7 | $50.6M |
| VANGUARD FIDUCIARY TRUST CO | 7 / 7 | $39.2M |
| JPMORGAN CHASE & CO | 7 / 7 | $21.7M |
Ranked by how many of Versant Venture Management, LLC's top 7 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. Common Stock | $68.7M | 4.38M | 45.5% | ▼−22% Reduced · −1.3M sh | |
| 2 | Lenz Therapeutics, Inc. Common Stock | $42.5M | 2.66M | 28.1% | —Held | |
| 3 | Jade Biosciences, Inc. Common Stock | $23.5M | 1.53M | 15.6% | —Held | |
| 4 | CRISPR Therapeutics AG Common Shares | $7.8M | 148.8K | 5.2% | —Held | |
| 5 | Contineum Therapeutics, Inc. Common Stock | $6.2M | 542.6K | 4.1% | —Held | |
| 6 | Skye Bioscience, Inc. Common Stock | $1.5M | 2.01M | 1.0% | —Held | |
| 7 | Tempest Therapeutics, Inc. Common Stock | $774K | 269.8K | 0.5% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1560009/holdings"
Use Arkolith to show Versant Venture Management, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 7 | $151.1M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 10, 2025 | 9 | $212.5M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 8 | $82.1M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 7, 2025 | 7 | $60.2M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 12, 2025 | 7 | $86.7M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 8, 2024 | 6 | $63.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.